Advice

following a full submission:

ertugliflozin (Steglatro®) is accepted for restricted use within NHSScotland.

Indication under review: in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:

  • As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.
  • In addition to other medicinal products for the treatment of diabetes.

SMC restriction: ertugliflozin is accepted for use as monotherapy and as add-on therapy. When used as monotherapy it is restricted to patients who would otherwise receive a dipeptidyl peptidase-4 inhibitor and in whom a sulphonylurea or pioglitazone is not appropriate.

ertugliflozin was superior to placebo in lowering HbA1c in adults with type 2 diabetes mellitus in phase III studies in monotherapy, dual therapy and triple therapy settings.

Medicine details

Medicine name:
ertugliflozin (Steglatro)
SMC ID:
SMC2102
Indication:
In adults aged 18 years and older with T2DM as an adjunct to diet and exercise to improve glycaemic control: • As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. • In addition to other medicinal products for the treatment of diabetes.
Pharmaceutical company
MSD
BNF chapter
Endocrine system
Submission type
Full submission
Status
Restricted
Date advice published:
14 January 2019